Novel Medications for Opiate Detoxification - 4

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000279

Purpose

The purpose of this study is to evaluate novel medications for opiate detoxification.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Clonidine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Novel Medications for Opiate Detoxification

Resource links provided by NLM:

Drug Information available for: Clonidine Clonidine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Withdrawal severity

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000279

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Study ID Numbers:	NIDA-09250-4, P50-09250-4
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000279 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Sympatholytics
Neurotransmitter Agents
Disease
Adrenergic alpha-Agonists
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Clonidine
Disorders of Environmental Origin
Cardiovascular Agents
Antihypertensive Agents
Opioid-Related Disorders

Adrenergic Agonists
Pharmacologic Actions
Pathologic Processes
Autonomic Agents
Sensory System Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 22, 2009